Related references
Note: Only part of the references are listed.Class of antiretroviral drugs and the risk of myocardial infarction
Nina Friis-Moller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine
C Fisac et al.
AIDS (2005)
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles?
E Fontas et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice
F Visnegarwala et al.
JOURNAL OF INFECTION (2004)
Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy.: Aquitaine Cohort, France, 1999-2001
F Bonnet et al.
HIV MEDICINE (2004)
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men
M Mary-Krause et al.
AIDS (2003)
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: The MaxCmin1 trial
UB Dragsted et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Cardiovascular disease risk factors in HIV patients -: association with antiretroviral therapy.: Results from the DAD study
N Friis-Moller et al.
AIDS (2003)
Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario
M Tumbarello et al.
AIDS (2003)
Protease inhibitors and cardiovascular outcomes in patients with HIV-1
SD Holmberg et al.
LANCET (2002)
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City
SS Shah et al.
CLINICAL INFECTIOUS DISEASES (2002)
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile
M van der Valk et al.
AIDS (2001)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
